Methylation and Chromatin Abnormalities in Myelodysplastic Syndromes and Chronic Myelomonocytic leukemia.


About this study

The purpose of this study is to assess tumor cells from blood and bone marrow from patients with myeloid neoplasms for epigenetic dysregulation and abnormalities of chromatin and for immune activation and exhaustion.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with myeloid neoplasms including MDS, MDS/MPN overlap syndromes and CMML

Exclusion Criteria: 

  • Any patients not meeting the above mentioned disease criteria.
  • Any patient who has declined participation in research activity.
  • For quarterly samples if hemoglobin is <8 gm/dl and/or HCT < 30%

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mrinal Patnaik, M.B.B.S.

Open for enrollment

Contact information:

Amy Phelps

(507) 284-0228

More information


Publications are currently not available

Mayo Clinic Footer